Multiple myeloma is not considered curable with current treatments, but it is highly treatable. Many patients live years or even decades after diagnosis, and a small percentage achieve remissions so deep and lasting that researchers describe them as “functionally cured.” The overall five-year survival rate is now 63.7%, roughly double what it was two decades ago, and newer therapies continue to push those numbers higher.
What “Treatable but Not Curable” Actually Means
When oncologists say multiple myeloma isn’t curable, they mean that even after successful treatment drives the cancer into remission, it almost always returns at some point. Treatment follows a pattern: you respond, you stay in remission for months or years, the myeloma comes back, and you start a new line of therapy. Each cycle can bring another remission, sometimes lasting as long as or longer than the previous one. This is why myeloma is increasingly managed as a chronic disease rather than a terminal one.
Not every patient needs treatment right away. A condition called smoldering myeloma produces no symptoms, and doctors may simply monitor it with regular testing, only starting therapy when the disease progresses. When treatment does begin, the goal is to reduce myeloma cells as deeply as possible and keep them suppressed for as long as possible.
The Concept of a Functional Cure
A small group of patients do so well after initial treatment that they never relapse, or at least not for many years. Researchers at one center defined a “functional cure” as remaining disease-free for more than seven years after frontline treatment. By that measure, about 9% of patients qualified. Their median time without disease progression was 10 years. These patients tended to share certain characteristics: lower-stage disease at diagnosis, no high-risk genetic abnormalities, little or no kidney damage, and very deep responses to treatment.
When researchers tested these long-term survivors for leftover cancer cells using highly sensitive methods, 61% had no detectable disease at all. This doesn’t guarantee the myeloma is gone forever, but it suggests that for a subset of patients, current treatments can come remarkably close to a cure in practical terms.
Why Depth of Remission Matters
How thoroughly treatment eliminates myeloma cells turns out to be one of the strongest predictors of how long remission lasts. Doctors measure this with something called minimal residual disease (MRD) testing, which looks for tiny traces of cancer that standard tests can’t detect. Patients who test MRD-negative have significantly better outcomes.
In a large meta-analysis, MRD-negative patients had a median progression-free survival of 54 months compared to 26 months for those who still had detectable disease. Even among patients already in complete remission by standard criteria, MRD status made a meaningful difference. At five years, 48% of MRD-negative patients remained disease-free versus 27% of MRD-positive patients. At seven years, those numbers were 37% and 14%. Achieving the deepest possible remission is one of the most important things treatment can accomplish.
How Stem Cell Transplant Extends Remission
For patients healthy enough to tolerate it (typically those under 65 to 70), autologous stem cell transplant remains a cornerstone of initial treatment. The procedure uses high-dose chemotherapy to wipe out as many myeloma cells as possible, then restores the bone marrow with the patient’s own previously collected stem cells.
Real-world data shows the benefit clearly. Patients who underwent transplant had a median progression-free survival of 73.8 months, just over six years, compared to 35.6 months for those who didn’t. That’s roughly double the time before the disease returns. Transplant doesn’t cure myeloma on its own, but it deepens the initial response and buys substantially more time.
CAR-T Therapy and Bispecific Antibodies
The newest treatments for myeloma harness the immune system to hunt down cancer cells, and their results in patients who have run out of other options are striking. CAR-T cell therapy involves collecting a patient’s own immune cells, engineering them in a lab to recognize myeloma, and infusing them back. In patients with relapsed or treatment-resistant disease, overall response rates range from 81% to 98%, with complete remission rates between 33% and 83% depending on the study.
In one cohort of 141 patients treated with CAR-T therapy, 90% responded and 48% achieved complete remission. Those who reached complete remission stayed disease-free for a median of over 42 months. Some patients maintained remissions lasting more than four years, with the longest at 5.6 years. Still, about half of complete remission patients eventually relapsed within four years, underscoring that even these powerful therapies haven’t yet crossed the line into a definitive cure for most people.
Bispecific antibodies work differently, acting as a bridge that physically connects immune cells to myeloma cells so the immune system can destroy them. One such therapy achieved a 61% response rate in patients who had already failed a median of five prior treatments, with 39% reaching complete remission. These drugs can be given as ongoing injections rather than requiring the complex manufacturing process of CAR-T, making them more accessible. The tradeoff is a significant infection risk, since these therapies suppress parts of the immune system that fight bacteria and viruses.
Genetic Risk Changes the Picture
Not all myeloma behaves the same way. Certain genetic abnormalities in the cancer cells make the disease more aggressive and harder to treat. About 10 to 20% of patients have what’s classified as high-risk disease based on these markers, and they face a much shorter timeline, with some experiencing progression within two to three years of diagnosis despite treatment.
When multiple high-risk genetic abnormalities occur together, the outlook worsens further. These patients are less likely to achieve deep remissions and more likely to relapse quickly. Genetic testing at diagnosis is essential because it shapes treatment decisions. High-risk patients are often treated more aggressively from the start, sometimes with combinations that include newer immunotherapies earlier in the course of disease.
How Age Affects Survival
Age at diagnosis is one of the most influential factors in myeloma outcomes, partly because younger patients tolerate more intensive treatments like stem cell transplant, and partly because older patients face competing health risks. Five-year survival for patients under 65 is about 62%, compared to roughly 48% for those aged 65 to 74, and 34% for those 75 and older. Patients over 70 face more than three times the mortality risk of those diagnosed before age 40.
The encouraging news is that survival has improved dramatically across every age group. Between the mid-1990s and the early 2010s, five-year survival nearly doubled for patients under 65 (from 38% to 62%) and rose from 21% to 34% for those 75 and older. The treatments introduced since then, including CAR-T and bispecific antibodies, aren’t yet fully reflected in these population-level statistics, so the real numbers today are likely better still.
What This Means in Practical Terms
If you or someone you care about has been diagnosed with multiple myeloma, the honest answer is that a true cure isn’t available yet for most patients. But “not curable” no longer means what it once did. Many people live 10 years or more after diagnosis. A growing minority achieve remissions so deep they may never need treatment again. And the treatment landscape is evolving faster than at any point in the disease’s history, with each new therapy option extending the time patients can live well.
The most important factors in your individual outlook are the genetic profile of your myeloma, how deeply your initial treatment drives down the disease, and whether you’re able to receive intensive therapies like transplant or immunotherapy. These are conversations worth having in detail with a myeloma specialist, ideally at a center experienced in the full range of current treatments.